6th EMEA forum on cardiovascular risks18 November 2017 - Lisbon, Portugal

rEgionAl workshop

FinAl progrAMME

gE

nE

rA

l i

nF

o

gEnErAl inForMAtion

4

OverviewThis live educational conference will look at available evidence on specific and relevant topics related to cardiovascular disease. Discussion will focus on increased sympathetic activity in the pathogenesis of hypertension-related heightened cardiovascular risk and the need to consider high heart rate as a target for treatment. The role of combination treatment in hypertension and recent novelties in the availability of fixed dose formulations will also be addressed. Treating the main hypertension - related clinical conditions, including acute coronary syndrome and heart failure, will also be discussed. Another major topic of interest will be to the optimal timeline for treating diabetic patients with beta-blockers and if there are differences among different molecules of this class.Time will also be dedicated to interactive clinical case discussions which will translate results from controlled clinical trials and guidelines into applications for daily clinical practice.

Learning objectivesBy attending this live educational programme, participants will be able to:•Highlight sympathetic nervous system over activity as a pathogenetic mechanism in

hypertensive-related cardiovascular risk and discuss if this parameter can be considered a target in antihypertensive treatment

•Discuss the role of fixed dose combinations in the treatment of hypertension and address the therapeutic relevance of the new fixed dose combination beta-blocker/calcium antagonist

•Identify the best practice according to guidelines for treating hypertensive patients with coronary artery disease

•Manage the complex transition from hypertension to heart failure and discuss the possible beneficial effect of pharmacological treatment

•Select the best beta-blocker compound when treating patients with diabetes

Target audienceThis programme is intended for cardiologists and internists involved in preventing and managing patients with cardiovascular risk factors or who are experiencing cardiovascular diseases.

Chairgiuseppe ManciaProfessor EmeritusUniversity of Milano-BicoccaMilan, Italy

6th EMEA forum on cardiovascular risks

5

Cme Provider EXCEMED is a non-profit foundation dedicated, since the last four decades, to the development of high-quality medical education programmes all over the world. EXCEMED adheres to the guidelines and standards of the European Accreditation Council for Continuing Medical Education (EACCME®) which states that continuing medical education must be balanced, independent, objective and scientifically rigorous.

EXCEMED adheres to the principles of the Good CME Practice group (gCMEp).

Continuing medical educationThe event 6th EMEA forum on cardiovascular risks is accredited by the European Board for Accreditation in Cardiology (EBAC) for 5 (five) hours of External CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

6

VenueThis live educational workshop takes place at the:lisbon Congress CenterPraça das Indústrias1300-307 Lisbon, Portugal

LanguageThe official language of this live educational workshop is English.

CME ProviderEXCEMED - Excellence in Medical EducationProgramme and Relations Manager: Flaminia Masprone T +39 06 420413 206 - F +39 06 420413 677 flaminia.masprone@excemed.org

For any logistic inquiry, please contact:Meridiano Congress International Event Manager: Luisa Di Salvo T +39 06 88 595 301 - F +39 06 88595 234 luisa.disalvo@meridiano.it

7

Follow us on

Our programme allows you to add your voice to the conversation. We wish you a unique learning experience.Express your opinion, pose questions and engage with us. During this conference we offer feedback formats suited to all tastes: case studies, Q&A with the experts and question cards. Our objective is to help you get the most from your learning experience with us.

Any questions for the experts? Please ask: use a question card.

FACUltY

FAC

Ult

Y

10

Faculty

Erland ErdmannDepartment of CardiologyUniversity of KölnKöln, Germany

Daniel FerreiraHead of Clinical Cardiology - Cardiovascular Center Hospital da Luz LisboaClinical Director - Hospital da Luz Digital Clinical Center Vice-President - Portuguese Society of Cardiology

guido grassiClinica Medica University of Milano-BicoccaMilan, Italy

giuseppe ManciaProfessor EmeritusUniversity of Milano-BicoccaMilan, Italy

harry A.J. struijker-BoudierMaastricht UniversityMaastricht, The Netherlands

stefano taddeiHypertension UnitDepartment of Clinical and Experimental MedicineUniversity of PisaPisa, Italy

Brian tomlinsonDepartment of Medicine and TherapeuticsThe Chinese University of Hong KongHong Kong SAR, China

11

progrAMME

pr

og

rA

MM

E

14

08.15 welcome D. Ferreira (Portugal)

08.20 opening and introduction G. Mancia (Italy)

session i

08.30 l1 sympathetic nervous system and cardiovascular risk G. Mancia (Italy)

08.50 l2 should increased heart rate be considered a target in cardiovascular treatment? H.A.J. Struijker-Boudier (The Netherlands)

09.10 l3 new possibilities for the fixed-dose combination treatment in hypertension S. Taddei (Italy)

09.30 panel discussion

09.50 Coffee break

session ii

10.10 l4 Best practice in the management of stable chronic angina B. Tomlinson (Hong Kong)

10.30 l5 From hypertension to heart failure: prevention strategies E. Erdmann (Germany)

10.50 l6 Use of betablockers in diabetes G. Grassi (Italy)

11.10 panel discussion

saturday, 18 november 2017

legend

l: Lecture : Working groups : Panel discussion

15

session iii workshops

11.30 parallel working groups

This session includes two different parallel workshops, each lasting 1 hour. Participants will be divided into groups and will attend both workshops in rotation. By the end of the session each participant will have attended both workshops.

group 1 group 2

11.30 - 12.30 11.30 - 12.30

the role of beta-blockers in hypertensive patientspresenter: H.A.J. Struijker-Boudier (The Netherlands)Discussant: B. Tomlinson (Hong Kong)

how to optimize treatment in patients with heart failure presenter: E. Erdmann (Germany)Discussant: S. Taddei (Italy)

12.30 - 13.30 12.30 - 13.30

how to optimize treatment in patients with heart failure presenter: E. Erdmann (Germany)Discussant: S. Taddei (Italy)

the role of beta-blockers in hypertensive patientspresenter: H.A.J. Struijker-Boudier (The Netherlands)Discussant: B. Tomlinson (Hong Kong)

13.30 Back to plenary room

13.35 From working groups to clinical practice: interactive discussion G. Mancia (Italy)

13.50 Closing remarks G. Mancia (Italy)

14.00 End of the workshop

Closing lunch

16

Faculty disclosures

EXCEMED adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programmes awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the programme (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the programme and all programme-related materials neither imply an endorsement nor a recommendation on the part of EXCEMED. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant relationship with commercial supporters and/or discussion of investigational or non-EMEA/FDA approved (off-label) uses of drugs.

Erland Erdmann Declared receipt of grants and contracts, of honoraria or consultation fees from Merck and Novartis and participation in Merck, ResMed and Bayer speaker’s bureau

Daniel Ferreira Declared receipt of honoraria or consultation fees from Bayer, Astellas, and BMS/Pfizer

guido grassi Declared receipt of honoraria or consultation fees from Menarini, Merck, Astra-Zeneca and CVRx

giuseppe Mancia Declared receipt of honoraria or consultation fees from Actavis, Amgen, Boehringer, CVRx, Daiichi Sankyo, Ferrer, Medtronic, Menarini, Merck, Novartis, Recordati, Sanofi and Servier

harry A.J. struijker-Boudier Declared receipt of grants and contracts from Durect and of honoraria or consultation fees from Merck and Servier

stefano taddei Declared receipt of grants and contracts from Novartis, Servier and Boehringer and participation in Servier and Pfizer speaker’s bureau

17

Brian tomlinson Declared receipt of grants and contracts from Amgen, AstraZeneca, Merck Serono, Merck Sharp & Dohme, Novartis, Pfizer and Roche, receipt of honoraria or consultation fees from Amgen, AstraZeneca, Merck Serono and Sanofi, to be member of Amgen and Sanofi advisory boards and participation in Amgen, Merck Serono and Sanofi speaker’s bureau.

BiogrAphiEs

Bio

gr

Ap

hiE

s

20

Erland Erdmann

Department of CardiologyUniversity of KölnKöln, Germany

Erland Erdmann, was head of the cardiac catheterization laboratory of the University of Munich before he was elected head of the department of Internal Medicine of the University of Cologne. From 1993 – 2012 he served as director of the clinic for cardiology, angiology, pneumology and intensive care medicine in the heart center of the university of Cologne. His main scientific interests are pathophysiology and treatment options of heart failure as well as the role of diabetes in cardiovascular disease. He has served in the steering committees of several major international drug and device trials directed to improve cardiovascular diseases such as CIBIS I – III, CARE-HF, PROACTIVE, SERVE-HF (all of which have been published in NEJM or The Lancet). Prof. Erdmann is editor of the main German textbook of cardiology (Klinische Kardiologie), now in the 8th edition and editor of several scientific journals among

them the Deutsche Medizininische Wochenschrift (German weekly medical journal).

21

Daniel Ferreira

Head of Clinical Cardiology - Cardiovascular Center Hospital da Luz LisboaClinical Director - Hospital da Luz Digital Clinical Center Vice-President - Portuguese Society of Cardiology

Daniel Ferreira is Head of the Clinical Cardiology at the Hospital da Luz in Lisbon, Clinical Director of the Hospital da Luz - Digital Clinical Center, Vice-President of the Portuguese Society of Cardiology and Associate-Editor for the Portuguese Journal of Cardiology. After the graduation from the Faculty of Medicine of the Lisbon University (Portugal), he completed his training in Cardiology at Santa Maria Hospital in Lisbon. Doctor Ferreira is a consultant cardiologist, certified by the Portuguese College of Physicians for the Cardiology specialty and for the Medical Emergency competence. His main investigation areas lie on the Cardiac Intensive Care, Thrombosis, Pulmonary Embolism, Cardiopulmonary Resuscitation, e-Health and e-Cardiology. He is the author and/or co-author of more than 80 book chapters and articles in specialty journals. He is a member of several national and international medical societies and Fellow of

the European Society of Cardiology (FESC) and of the American College of Cardiology (FACC).

22

guido grassi

Clinica Medica University of Milano-BicoccaMilan, Italy

Guido Grassi is Full Professor of Internal Medicine at the Clinica Medica of the University of Milano-Bicocca, and Director of the Clinica Medica Institute at St Gerardo Hospital-Monza/Milano (Italy). He is also the Director of the Post-graduate School of Internal Medicine and of the PHD course in Public Health, University of Milan-Bicocca. He was Vice-Chairman (2002-2004) and then Chairman (2004-2006) of the Working Group “Hypertension and the Heart,” European Society of Cardiology. He serves as Treasurer and then Secretary of the Italian Society of Hypertension (2004-2007). In 2006-2007 he was a member of the Task Force of the European Society of Hypertension/European Society of Cardiology for the 2007 Guidelines on Hypertension. In 2007 he was appointed the “Wright Lecturer” at the Annual Meeting of the High Blood Pressure Council of Australia. He is a member of the Scientific Council of the International Society of Hypertension for the periods 2008-2012 and 2012-2016 and member of the Scientific Council of the European Society of Hypertension 2013-2016. In 2009 he received the Bjorn Folkow Award

and Lecture from the European Society of Hypertension. His research areas include the pathophysiology, clinical pharmacology and treatment of hypertension, obesity and metabolic syndrome, cardiac arrhythmias and heart failure. He has published more than 500 original papers and reviews in major scientific international journals (H index 70). He is Executive Editor of the Journal of Hypertension, Section Editor for the Journal of the American Society of Hypertension, Co-Editor of Current Hypertension Reviews and member of the Editorial Board of several major international journals. In 2014 he was included in the Top Ten Hypertension Expert Ranking made by Expertscape Ranks World’s Top Scientists. In 2017 he received the Talaj Zein Award from the European Society of Hypertension.

23

giuseppe Mancia

Professor EmeritusUniversity of Milano-BicoccaMilan, Italy

Giuseppe Mancia is Professor Emeritus at the University Milano-Bicocca, after 20 years as Chairman of the Division and Department of Internal Medicine at the same University at the San Gerardo Hospital in Monza and Director of the Interuniversity (Universities of Milano, Milano-Bicocca and Pavia) Center for Clinical Physiology and Hypertension. He was Chairman (2001,2003, 2005, 2007, 2009, 2011 and 2013) of the Scientific and Organizing Committee of ESH meetings, and past President of the ISH, ESH, European Society of Clinical Investigation and Italian Society of Hypertension. He has chaired the Task Force of the ESH/ESC Hypertension Guidelines in 2003, 2007, 2009 and 2013. He is currently Chairman of the ESH Foundation and the Hypertension Center, Policlinico of Monza. He is the honorary member of several hypertension and cardiovascular societies and has received many Awards, including the Heymans Award of the International Society of Pharmacology, the Volhard and Tigersted Awards of the ISH, the Folkow Award of the ESH, the International Recordati Prize, the

Invernizzi Prize of Medicine, the Spinoza Honorary Professorship of the University of Amsterdam, the Gold Medal of the Lorenzini Foundation, the Honorary Professorship of the University of Cordoba, a Honoris Causa Doctorate in Medicine from the University of Gdansk, Bucharest (Carol Davila) and Glasgow, the Hariri Memorial Lecture and Award and the MacDonald Award from McMaster University (Canada). Professor Mancia’s research focuses on the epidemiology, pathophysiology, diagnosis and treatment of hypertension, heart failure, coronary and other cardiovascular diseases. He is interested in ambulatory blood pressure monitoring, neural control of the circulation, large artery mechanics, hemodynamic of cardiovascular drugs, and clinical trials. He has edited several books on hypertension and cardiovascular diseases, and has published over 1.800 papers in international Journals. His papers have received more than 117.000 citations (H-index 148), for which he is in the Thompson Reuters list of the world’s highly cited scientists.

24

harry A.J. struijker-Boudier

Maastricht UniversityMaastricht, The Netherlands

Harry Struijker-Boudier is Professor Emeritus of Pharmacology at Maastricht University, The Netherlands. He graduated in 1973 in Pharmacochemistry and Biochemistry and obtained his Ph.D. in Pharmacology in 1975 from the Radboud University Nijmegen, the Netherlands. Struijker-Boudier worked as a post-doc in the Department of Physiology and Biophysics of the University of Mississippi Medical School in Jackson, Miss., USA in 1976-1977 and took up a position in the newly created Department of Pharmacology at Maastricht University in 1977. He was appointed Professor of Experimental Pharmacology in 1980 and as chairman of the Department of Pharmacology and Toxicology in 1984. He spent a sabbatical year as visiting professor at the INSERM Unit 141 at the Hôpital Lariboisière in Paris during 1991. From 1999-2006 he served as scientific director of the Cardiovascular Research Institute Maastricht (CARIM). Struijker-Boudier has published more than 500 scientific papers in peer-reviewed

international journals and books in the areas of cardiovascular pharmacology, hypertension, heart failure and drug design and delivery. The total number of citations of his articles is >25,000. He has served as board member of numerous international organizations, e.g. vice-president of the scientific council of the European Society of Hypertension and board member of the European Federation of Pharmacological Societies. He is doctor honoris causa of the Université de Liège, Belgium, recipient of the Descartes-Huygens prize of the French Government, member of the Dutch Royal Society of Sciences and Officer of the Order of Oranje-Nassau of the Dutch Royal House.

25

stefano taddei

Hypertension UnitDepartment of Clinical and Experimental MedicineUniversity of PisaPisa, Italy

Stefano Taddei was born in Pisa, Italy, in 1957. He attended the State University of Pisa, where he graduated in Medicine and Surgery in 1982 and specialized in Clinical Pharmacology in 1986. Prof. Taddei is Professor of Internal Medicine. He is currently Director of the Hypertension Unit of the Department of Clinical and Experimental Medicine. Prof. Taddei is a Fellow of the European Society of Cardiology, the European, International and American Societies of Hypertension, the European Society of Clinical Investigation, the High Blood Pressure Council of the American Heart Association and of the Italian Society of Hypertension. He has served as a councilor of the Italian Society of Hypertension (2007-2009). He is a member of the Editorial Boards of Hypertension, Blood Pressure, Journal of Cardiovascular Pharmacology, Current Hypertension Reviews, High Blood Pressure and Cardiovascular Prevention and Journal of American

Society of Hypertension. He is an International Associated Editor of the European Heart Journal. His main research area is local neuro-humoral control of peripheral vessels in primary and secondary forms of hypertension, with particular emphasis on the sympathetic nervous system, the renin-angiotensin system and the endothelium. He is also interested in the assessment of target-organ damage in hypertension, including vascular and cardiac structural alterations and the clinical pharmacology of cardiovascular drugs. Prof. Taddei has participated in numerous clinical studies and is the authors of more than 300 original papers, reviews and editorials in international scientific journals (H index: 55; Impact Factor: >1400).

26

Brian tomlinson

Department of Medicine and TherapeuticsThe Chinese University of Hong KongHong Kong SAR, China

Brian Tomlinson was formerly Chair Professor in the Department of Medicine and Therapeutics and Head of the Division of Clinical Pharmacology at the Chinese University of Hong Kong and honorary Consultant Physician at the Prince of Wales Hospital, Hong Kong. He trained in internal medicine and Clinical Pharmacology at the Middlesex Hospital Medical School and University College Hospital, London and received his MD from the University of London.His clinical and research interests include the clinical pharmacology, toxicology and pharmacogenetics of drugs, particularly in the cardiovascular field, and the pathogenesis and treatment of hyperlipidaemia, hypertension, the metabolic syndrome and diabetes. He has trained over 30 postgraduate students and is an author of over 350 publications and over 500 conference abstracts and has given numerous invited lectures. He is a reviewer for many journals and

serves on several Editorial Boards and is President of the Asian-Pacific Society of Atherosclerosis and Vascular Diseases and Secretary General of the Pacific Rim Association for Clinical Pharmacogenetics.

27

lEArning oBJECtivEs

lEAr

nin

g oB

JECt

ivEs

30

sympathetic nervous system and cardiovascular riskG. Mancia (Italy)L1

NOTES

Learning objectives:•Describe the relationship between sympathetic nervous system activity and

cardiovascular risk•Discuss mechanisms responsible for increased cardiovascular risk determined by

sympathetic nervous system (SNS) overactivity•Illustrate methods to measure SNS activity in clinical practice •Identify whether reduction in sympathetic activity is associated with better outcomes

in patients with high cardiovascular risk

31

should increased heart rate be considered a target in cardiovascular treatment?H. A.J. Struijker-Boudier (The Netherlands)L2

NOTES

Learning objectives:•Describe HR targets in hypertensive patients•Discuss which type of investigation should be performed•Illustrate possible therapeutic strategies •Predict the expected therapeutic benefits

32

new possibilities for the fixed-dose combination treatment in hypertensionS.Taddei (Italy)L3

NOTES

Learning objectives:•Describe the difficulty of reaching blood pressure targets in hypertensive patients•Discuss the pharmacological principles of combination therapy•Illustrate the most important trials addressing the efficacy of different combination

strategies•Identify advantages of combinations not including RAS blockers

33

Best practice in the management of stable chronic anginaB. Tomlinson (Hong Kong)L4

NOTES

Learning objectives:•Describe the prevalence and associated cardiovascular risk of patients with stable chronic

angina•Discuss the main mechanisms leading to an established chronic coronary artery disease•Illustrate the best therapeutic strategy according to international guidelines•Identify specific effects of beta-blockers in coronary artery disease

34

From hypertension to heart failure: prevention strategiesE. Erdmann (Germany)L5

NOTES

Learning objectives:•Describe different mechanisms through which hypertension can lead to heart failure•Discuss differences between heart failure with reduced or preserved ejection fraction•Illustrate optimal treatment according to the evidence of controlled clinical trials•Identify the best strategy to manage follow-up

35

Use of betablockers in diabetesG. Grassi (Italy)L6

NOTES

Learning objectives:•Describe the relationship between diabetes and coronary artery disease•Discuss the need to reduce coronary artery disease in diabetes•Illustrate the metabolic effects of beta blockers•Identify the best option among the different molecules of the class of beta-blockers

36

the role of beta-blockers in hypertensive patientsH. A.J. Struijker-Boudier (The Netherlands)B. Tomlinson (Hong Kong)

WG1

NOTES

Learning objectives:•Describe the relevance of heart rate in determining a patient’s cardiovascular •Discuss the clinical approach and differential diagnosis for this patient•Illustrate the possible options for pharmacological treatment•Identify clinical differences among the various molecules within the beta-blocker class

37

how to optimize treatment in patients with heart failureE. Erdmann (Germany) S. Taddei (Italy)

WG2

NOTES

Learning objectives:•Describe the clinical conditions of the patient•Discuss whether a better treatment might improve prognosis•Illustrate the best clinical approach to a specific patient•Identify how the treatment might be improved

38

NOTES

39

NOTES

40

NOTES

41

NOTES

42

NOTES

43

NOTES

44

NOTES

45

NOTES

46

All EXCEMED programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of EXCEMED. This programme is made possible thanks to educational grants received from Merck KGaA, Darmstadt, Germany and San Raffaele Hospital, Milan, Italy.

EXCEMED - Excellence in Medical Education 14, Rue du Rhône, 1204 Geneva, Switzerland

Improving the patient’s life through medical education

www.excemed.org

Copyright © eXCemeD, 2017. All rights reserved.